Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Seer, Inc.NASDAQ: SEER

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $1.81M fell 15.5% year over year, ahead of the -27.0% change in trailing-twelve-month cost of revenue. Sequentially, it fell 10.3% from the prior quarter. Over 3 fiscal years it compounded at -0.2% a year.

Context

  • Cost of revenue amounted to 88.2% of revenue in FY2025, up 37.2 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -15.5% holds above the trailing-twelve-month pace of -27.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.81M-10.3% QoQ
Last fiscal yearDec 2025
$14.22M+99.8% YoY
LTMMar 2026
$7.78M-27.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.5%——
1 year+99.8%——
3-year CAGR-0.2%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
14.22M USD
Year-over-year change
+99.8%
4-year CAGR
+20.4%

Cost of Revenue vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -27.0% is the 7th highest of 13, against a peer median of -16.6%.
  • Cost of revenue amounts to 51.7% of revenue for SEER, versus a peer median of 60.0%.
SEER Competitors
Cost of Revenue for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$94.76M USD-56.9%-53.2%13.5%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$21.94M USD——77.7%
SEERSeer, Inc.LTM Mar 2026$7.78M USD-27.0%-0.2%51.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 2.61M CHF-92.3%-62.9%—
SANASana Biotechnology, Inc.LTM Mar 2026$2.39M USD———
NKTXNkarta, Inc.LTM Mar 2026$2.34M USD———
LYELLyell Immunopharma, Inc.LTM Mar 2026$2.33M USD——7522.6%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$2.03M USD-1.5%—4.7%
STTKShattuck Labs, Inc.LTM Mar 2026$1.82M USD-36.2%—182.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$1.8M USD-69.3%—5.2%
PEPGPepGen Inc.LTM Mar 2026$1.72M USD+351.6%——
QSIQuantum-Si incorporatedLTM Mar 2026$1.11M USD-31.7%—60.0%
MNOVMediciNova, Inc.LTM Mar 2026$505.96K USD+9673.3%—84.8%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$320K USD+5.3%——
PHVSPharvaris N.V.LTM Sep 2026€106.45K EUR+9.7%——
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$79K USD+2.6%——
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$21K USD———
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 USD———
KYMRKymera Therapeutics, Inc.LTM Jun 2026-$2.08M USD-200.0%—2.0%
Peer median (excluding SEER) —-16.6%-58.1%60.0%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.39M14.69M15.18M13.95M16.12M
Cost of Revenue6.77M14.3M13.73M7.12M14.22M
Gross Profit(374K)384K1.45M6.83M1.9M
Gross Margin-5.8%2.6%9.5%49.0%11.8%
Research & Development29.12M45.8M47.44M50.59M37.77M
Selling, General & Admin42.2M52.63M58.95M56.57M42.58M
Operating Expenses71.32M98.43M106.39M106.93M80.35M
Depreciation & Amortization3.56M5.9M5.58M6.18M6.1M
EBITDA(67.61M)(87.07M)(80.7M)(80.33M)(67.3M)
EBITDA Margin-1057.3%-592.9%-531.5%-575.9%-417.5%
Operating Income(71.7M)(98.04M)(104.94M)(100.1M)(78.45M)
Operating Margin-1121.3%-667.6%-691.2%-717.7%-486.7%
Interest Income326K4.6M17.76M16.67M11.52M
Interest Expense22K0000
Other Income / Expenses527K5.08M18.67M13.6M5.05M
Income Before Tax(71.17M)(92.97M)(86.28M)(86.5M)(73.4M)
Pre-Tax Margin-1113.1%-633.1%-568.3%-620.2%-455.4%
Income Tax Expense00098K201K
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Net Margin-1113.1%-633.1%-568.3%-620.9%-456.6%
EPS (Basic)(1.13)(1.42)(1.35)(1.39)(1.28)
EPS (Diluted)(1.13)(1.42)(1.35)(1.39)(1.28)
Weighted Avg Shares60.86M62.43M63.85M62.35M57.45M
Weighted Avg Shares (Diluted)60.86M62.43M63.85M62.35M57.45M

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.